Tag: T cell engagers
-
AI-Powered Drug Discovery: Transforming Cancer Therapy Selection
Ardigen and VERAXA Biotech are collaborating to enhance cancer therapy development through AI-driven target pair selection, aiming to optimize T cell engagers and antibody-drug conjugates. This approach could significantly improve patient outcomes by minimizing side effects and improving therapeutic efficacy. Read more
-
AI-Driven Precision Oncology: Enhancing Cancer Therapy Development
Ardigen and VERAXA Biotech are collaborating to enhance precision oncology through AI-driven drug discovery, optimizing cancer target selection for T cell engagers and antibody-drug conjugates. This partnership aims to minimize toxicities and improve success rates in cancer therapies. Read more
